Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC?risk groups in metastatic renal cell carcinoma: a meta-analysis.
Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Ricci AD, Grilli G, Greco A, Montironi R, Ardizzoni A, Massari F. Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC?risk groups in metastatic renal cell carcinoma: a meta-analysis. Immunotherapy. 2021 06; 13(9):783-793.